Therapeutics Discovery is advancing cancer care
At the core of MD Anderson’s approach to patient care is our pioneering work in basic science, translational research and clinical studies. Like many institutions around the globe, MD Anderson has suspended our laboratory research and limited our clinical trials in response to the COVID-19 pandemic.
However, before the pause in research, our experts made significant advances in cancer prevention and treatment. They will be sharing their findings at the AACR Virtual Annual Meetings I and II. Keep up with the latest and learn about our other practice-changing research below.
Our researchers are resilient. Their resolve to understand more about cancer continues to drive their commitment to learning, collaborating, educating and mentoring. Their work will resume, and we will make progress toward seeing a world without cancer.
Phase III EMBRACA clinical trial survival benefit results may be
affected by subsequent treatments
Glutaminase inhibitor IPN60090 currently in Phase I clinical
Twelve MD Anderson researchers honored with 2020 AACR Team Science Awards
The American Association for Cancer Research (AACR) is recognizing the founding members of The Cancer Genome Atlas (TCGA) and the current project team with 2020 AACR Team Science Awards. These teams will be honored during the AACR Virtual Annual Meeting II on June 24.
Moon Shots Program
MD Anderson’s Moon Shots® Program aims to rapidly and dramatically improve the disease's survival rates and reduce suffering through early detection, research and new treatments.Learn more about the Moon Shots Program
MD Anderson News
The Therapeutics Discovery division at MD Anderson was created to eliminate the bottlenecks that hamper traditional drug development.
Consisting of more than 100 dedicated cancer researchers, doctors, drug developers and scientific experts, our team develops small molecule drugs, biologics and cellular therapies. We're inspired by the needs of our patients and guided by the expertise of the center’s clinicians. We don't bring the “bench to bedside” – we start with the bench at the bedside – with each patient and their cancer.
Education and Training
Education is at the core of our work to end cancer. Through our comprehensive and competitive programs, we are committed to training the next generation to join the fight.
ENJOY SCIENCE Seminar Series
Despite the limitations presented by COVID-19, remain engaged and inspired during this difficult time with our ENJOY SCIENCE Seminar Series. Hear from our experts as they highlight the latest in clinical and mechanistic research taking place at MD Anderson.
During these challenging times, anxiety is running high and it's important to stay mindful of self-care. We're all in this together, and we must all take steps to ensure we stay healthy.